A multicenter study in 15 hospitals suggested epigenomic profile based on a microarray DNA methylation signature (EPIMMUNE) could serve as an effective biomarker in predicting the outcomes of NSCLC patients treated with PD-1 inhibitors [65], and the FOXP1 could be a predictive biomarker for better-selecting patients to benefit with immunotherapy [65]. Here, PDCD1 is linked to non-small cell lung carcinoma.